Voyager Therapeutics (VYGR)
(Delayed Data from NSDQ)
$4.49 USD
+0.23 (5.28%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $4.48 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VYGR 4.49 +0.23(5.28%)
Will VYGR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VYGR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VYGR
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
VYGR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates
Other News for VYGR
VYGR forms Shooting Star Candlestick on September 17
VYGR's price rises by 0.95% on September 16, though its technical setup remains stable.
Is VYGR poised for gains? 200 Day Moving Average Support shows up after rising 0.72%
VYGR Makes Notable Cross Below Critical Moving Average
Voyager Therapeutics (VYGR): HC Wainwright & Co. Reiterates Buy Rating | VYGR Stock News